
|Articles|September 15, 2004
Six-month clinical results positive for dual-optic IOL
San Diego-First trial results with the Synchrony dual-optic accommodative IOL (Visiogen Inc.) indicate that this first-generation lens is safe and performs well. However, lens power calculations should improve via more IOL implantation and calculation adjustment, according to Gerd Auffarth, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
AAO 2025: Which lens to consider in patients with pseudoexfoliation
3
News from Orlando: AAO 2025 highlights research across all areas of eyecare
4
AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA
5